


IN THE CLAIMS (37 CFR 1.121 Revised)

Claim 1. (Previously Presented) A compound of the following formula II



or a pharmaceutically acceptable salt thereof, wherein

A is -CR₇ or N;

B is -NR₁R₂, -CR₁R₂R₁₁, -C(=CR₂R₁₂)R₁, -NHCHR₁R₂, -OCHR₁R₂, -SCHR₁R₂, -CHR₂OR₁, -CHR₁OR₂, -CHR₂SR₁, -C(S)R₂, -C(O)R₂, -CHR₂NR₁R₂, -CHR₁NHR₂, -CHR₁N(CH₃)R₂, or -NR₁₂NR₁R₂;

Y is CH or N;

R₁ is C(O)H, C(O)(C₁-C₆ hydrocarbyl), C(O)(C₁-C₆ hydrocarbylene)(C₃-C₈ cyclohydrocarbyl), C(O)(C₃-C₈ cyclohydrocarbylene)

(C₃-C₈ cyclohydrocarbyl), C(O)(C₁-C₆ hydrocarbylene)(C₄-C₈ heterocyclohydrocarbyl), -C(O)(C₃-C₈ cyclohydrocarbylene)(C₄-C₈ heterocyclohydrocarbyl), C₁-C₆ hydrocarbyl, C₃-C₈ cyclohydrocarbyl, C₄-C₈ heterocyclohydrocarbyl, -(C₁-C₆ hydrocarbylene)(C₃-C₈ cyclohydrocarbyl), C₃-C₈ cyclohydrocarbylene)(C₃-C₈ cyclohydrocarbyl), -(C₁-C₆ hydrocarbylene)(C₄-C₈ heterocyclohydrocarbyl), -(C₃-C₈ cyclohydrocarbylene)(C₄-C₈ heterocyclohydrocarbyl), or -O-aryl, or -O-(C₁-C₆ hydrocarbylene)-aryl; wherein said aryl, C₄-C₈ heterocyclohydrocarbyl, C₁-C₆ hydrocarbyl, C₃-C₈ cyclohydrocarbyl, C₃-C₈ cyclohydrocarbylene, and C₁-C₆ hydrocarbylene groups may each independently be optionally substituted with from one to six fluoro and may each independently be optionally substituted with one or two substituents R₈ independently selected from the group consisting of C₁-C₄ hydrocarbyl, -C₃-C₈ cyclohydrocarbyl, hydroxy, chloro, bromo, iodo, CF₃, -O-(C₁-C₆ hydrocarbyl), -O-(C₃-C₅ cyclohydrocarbyl), -O-CO-(C₁-C₄ hydrocarbyl), -O-CO-NH(C₁-C₄ hydrocarbyl), -O-CO-N(R₂₄)(R₂₅), -N(R₂₄)(R₂₅), -S(C₁-C₄ hydrocarbyl), -S(C₃-C₅ cyclohydrocarbyl), -N(C₁-C₄ hydrocarbyl)CO(C₁-C₄ hydrocarbyl), -NHCO(C₁-C₄ hydrocarbyl), -COO(C₁-C₄ hydrocarbyl), -CONH(C₁-C₄ hydrocarbyl), -CON(C₁-C₄ hydrocarbyl)(C₁-C₂ hydrocarbyl), CN, NO₂, -OSO₂(C₁-C₄ hydrocarbyl), S⁺(C₁-C₆ hydrocarbyl)(C₁-C₂ hydrocarbyl)I⁻, -SO(C₁-C₄ hydrocarbyl) and -SO₂(C₁-C₄ hydrocarbyl); and wherein the C₁-C₆ hydrocarbyl, C₁-C₆ hydrocarbylene, C₃-C₈ cyclohydrocarbyl, C₃-C₈ cyclohydrocarbylene, and C₃-C₈ heterocyclohydrocarbyl moieties of R₁ may optionally independently contain from one to three double or triple bonds; and wherein the C₁-C₄ hydrocarbyl moieties and C₁-C₆ hydrocarbyl moieties of R₈ can optionally independently be substituted with hydroxy, amino, C₁-C₄ alkyl, aryl, -CH₂-aryl, C₃-C₅ cycloalkyl, or -O-(C₁-C₄ alkyl), and can optionally independently be

substituted with from one to six fluoro, and can optionally contain one or two double or triple bonds; and wherein each heterocyclohydrocarbyl group of R_1 contains from one to three heteromoieties selected from oxygen, $S(O)_m$, nitrogen, and NR_{12} ;

R_2 is hydrogen, C_1 - C_{12} hydrocarbyl, C_3 - C_8 cyclohydrocarbyl, C_4 - C_8 heterocyclohydrocarbyl, $-(C_1$ - C_6 hydrocarbylene)(C_3 - C_8 cyclohydrocarbyl), $-(C_3$ - C_8 cyclohydrocarbylene)(C_3 - C_8 cyclohydrocarbyl), $-(C_1$ - C_6 hydrocarbylene)(C_4 - C_8 heterocyclohydrocarbyl), $-(C_3$ - C_6 cyclohydrocarbylene)(C_4 - C_8 heterocyclohydrocarbyl), aryl, $-(C_1$ - C_6 hydrocarbylene)aryl, or $-(C_3$ - C_8 cyclohydrocarbylene)(aryl); wherein each of the foregoing R_2 groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro, and C_1 - C_6 alkyl, wherein one of said one to three substituents can further be selected from bromo, iodo, C_1 - C_6 alkoxy, $-OH$, $-O-CO-(C_1$ - C_6 alkyl), $-O-CO-N(C_1$ - C_4 alkyl)(C_1 - C_2 alkyl), $-S(C_1$ - C_6 alkyl), $-S(O)(C_1$ - C_6 alkyl), $-S(O)_2(C_1$ - C_6 alkyl), $S^+(C_1$ - C_6 alkyl)(C_1 - C_2 alkyl) I-, CN, and NO_2 ; and wherein the C_1 - C_{12} hydrocarbyl, $-(C_1$ - C_6 hydrocarbylene), and cyclohydrocarbyl groups of 5 - 8 carbon atoms, cyclohydrocarbylene groups of 5 to 8 carbon atoms and heterocyclohydrocarbyl groups of 5 to 8 atoms of R_2 may optionally independently contain from one to three double or triple bonds; and wherein each heterocyclohydrocarbyl group of R_2 contains from one to three heteromoieties selected from oxygen, $S(O)_m$, nitrogen, and NR_{12} ; or when R_1 and R_2 are as in $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_1R_2$ or $-NR_1R_2$, R_1 and R_2 of B may form a 5- to 8-membered ring which may be saturated or contain one or two double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen, $S(O)_m$, nitrogen or NR_{12} ; and which carbocyclic ring can optionally be substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, C_1 - C_4 alkyl, fluoro, chloro,

bromo, iodo, CF₃, -O-(C₁-C₄ alkyl), -O-CO-(C₁-C₄ alkyl), -O-CO-NH(C₁-C₄ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -NH(C₁-C₄ alkyl), -N(C₁-C₂ alkyl)(C₁-C₄ alkyl), -S(C₁-C₄ alkyl), -N(C₁-C₄ alkyl)CO(C₁-C₄ alkyl), -NHCO(C₁-C₄ alkyl), -COO(C₁-C₄ alkyl), -CONH(C₁-C₄ alkyl), -CON(C₁-C₄ alkyl)(C₁-C₂ alkyl), CN, NO₂, -OSO₂(C₁-C₄ alkyl), -SO(C₁-C₄ alkyl), and -SO(C₁-C₄ alkyl), wherein one of said one to three substituents can further be selected from phenyl;

R₃ is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF₃, NH₂, NH(C₁-C₂ alkyl), N(CH₃)₂, -NHCOCF₃, -NHCH₂CF₃, S(O)_m(C₁-C₄ alkyl), CONH₂, -CONHCH₃, CON(CH₃)₂, -CF₃, or CH₂OCH₃;

R₄ is hydrogen, C₁-C₄ hydrocarbyl, C₃-C₅ cycloalkyl, -(C₁-C₄ hydrocarbylene)(C₃-C₅ cycloalkyl), -(C₃-C₅ cycloalkylene)(C₃-C₆ cycloalkyl), cyano, fluoro, chloro, bromo, iodo, -OR₂₄ C₁-C₆ alkoxy, -O- cycloalkyl), -O-(C₁-C₄ hydrocarbylene)(C₃-C₅ cycloalkyl), -O-(C₃-C₅ cycloalkylene)(C₃-C₅ cycloalkyl), -CH₂SC(S)O(C₁-C₄ alkyl), CH₂OCF₃, CF₃, amino, nitro, -NR₂₄R₂₅, -(C₁-C₄ hydrocarbylene)-OR₂₄, -(C₁-C₄ hydrocarbylene)Cl, -(C₁-C₄ hydrocarbylene)NR₂₄R₂₅, -NHCOR₂₄, -NHCONR₂₄R₂₅, -CH=NOR₂₄, -NHNR₂₄R₂₅, -S(O)_mR₂₄, -C(O)R₂₄, -OC(O)R₂₄, -C(O)CN, -C(O)NR₂₄R₂₅, -C(O)NHNR₂₄R₂₅, and -COOR₂₄, wherein the hydrocarbyl and hydrocarbylene groups of R₄ may optionally independently contain one or two double or triple bonds and may optionally independently be substituted with one or two substituents R₁₀ independently selected from hydroxy, amino, -NHCOCH₃, -NHCOCH₂Cl, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)(C₁-C₂alkyl), -COO(C₁-C₄ alkyl), -COOH, -CO(C₁-C₄ alkyl), C₁-C₆ alkoxy, C₁-C₃ thioalkyl, cyano and nitro, and with one to four substituents independently selected from fluoro and chloro;

R_5 is aryl or heteroaryl and is substituted with from one to four substituents R_{27} independently selected from halo, C_1 - C_{10} hydrocarbyl, $-(C_1-C_4 \text{ hydrocarbylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_1-C_4 \text{ hydrocarbylene})(C_4-C_8 \text{ heterocycloalkyl})$, $-(C_3-C_8 \text{ cycloalkyl})$, $-(C_4-C_8 \text{ heterocycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_4-C_8 \text{ heterocycloalkyl})$, C_1 - C_4 haloalkyl, C_1 - C_4 haloalkoxy, nitro, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, $-CON(OR_{22})R_{23}$, $-CO_2R_{26}$, $-C=N(OR_{22})R_{23}$, and $-S(O)_mR_{23}$; wherein said C_1 - C_{10} alkyl, C_3 - C_8 cycloalkyl, $(C_1-C_4 \text{ hydrocarbylene})$, $(C_3-C_8 \text{ cycloalkyl})$, $(C_3-C_8 \text{ cycloalkylene})$, and $(C_4-C_8 \text{ heterocycloalkyl})$ groups can be optionally substituted with from one to three substituents independently selected from C_1 - C_4 alkyl, C_3 - C_8 cycloalkyl, $(C_1-C_4 \text{ hydrocarbylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, C_1 - C_4 haloalkyl, hydroxy, C_1 - C_6 alkoxy, nitro, halo, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, $-CO(NOR_{22})R_{25}$, and $-S(O)_mR_{23}$; and wherein two adjacent substituents of the R_5 group can optionally form a 5-7 membered ring, saturated or unsaturated, fused to R_5 , which ring optionally can contain one, two, or three heterologous members independently selected from O, $S(O)_m$, and N, but not any $-S-S-$, $-O-O-$, $-S-O-$, or $-N-S-$ bonds, and which ring is optionally substituted with C_1 - C_4 alkyl, C_3 - C_8 cycloalkyl, $-(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, C_1 - C_4 haloalkyl, nitro, halo, cyano, $-NR_{24}R_{25}$, $-NR_{24}COR_{25}$, $-NR_{24}CO_2R_{26}$, $-COR_{24}$, $-OR_{25}$, $-CONR_{24}R_{25}$, $-CO(NOR_{26})R_{25}$, or $-S(O)_mR_{23}$; wherein one of said one to four optional substituents R_{27} , can further be selected from $-SO_2NH(C_1-C_4 \text{ alkyl})$, $-SO_2NH(C_1-C_4 \text{ alkylene})(C_3-C_8 \text{ cycloalkyl})$, $-SO_2NH(C_3-C_8 \text{ cycloalkyl})$, $-SO_2NH(C_3-C_8 \text{ cycloalkylene})(C_3-C_8 \text{ cycloalkyl})$, $-SO_2N(C_1-C_4 \text{ alkyl})(C_1-C_2 \text{ alkyl})$, $-SO_2NH_2$, $-NHSO_2(C_1-C_4 \text{ alkyl})$, $-NHSO_2(C_3-C_8 \text{ cycloalkyl})$, $-NHSO_2(C_1-C_4$

alkylene)(C₃-C₈ cycloalkyl), and -NHSO₂(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl); and wherein the hydrocarbyl, and hydrocarbylene groups of R₅ may independently optionally contain one double or triple bond;

R₆ is hydrogen, C₁-C₆ alkyl, C₃-C₈ cycloalkyl, -(C₁-C₆ alkylene)(C₃-C₈ cycloalkyl), or -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), wherein said alkyl and cycloalkyl may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

or R₆ and R₄ can together form an oxo (=O) group, or can be connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing one, two, or three heterologous ring members selected from O, SO_m, N, and NR₁₂, but not containing any -O-O-, -S-O-, -S-S-, or -N-S- bonds, and further optionally substituted with C₁-C₄ hydrocarbyl or C₃-C₆ cycloalkyl, wherein said C₁-C₄ hydrocarbyl substituent may optionally contain one double or triple bond;

R₇ is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C₁-C₂ alkyl), -O(cyclopropyl), -COO(C₁-C₂ alkyl), -COO(C₃-C₈ cycloalkyl), -OCF₃, CF₃, -CH₂OH, or CH₂OCH₃;

R₁₁ is hydrogen, hydroxy, fluoro, ethoxy, or methoxy;

R₁₂ is hydrogen or C₁-C₄ alkyl;

R₁₆ and R₁₇ are each, independently, hydrogen, hydroxy, methyl, ethyl, methoxy, or ethoxy, except that R₁₆ and R₁₇ are not both methoxy or ethoxy; or R₁₆ and R₁₇ together form an oxo (=O) group; or R₁₆ and R₁₇ are connected to form a 3-8 membered carbocyclic ring, optionally containing one to three double bonds, and optionally containing from one to three heterologous ring members selected from O, SO_m, N, and NR₁₂, but not containing any -O-O-, -S-O-, -S-S-, or -N-S- bonds, and further optionally substituted with C₁-C₄

hydrocarbyl or C₃-C₆ cycloalkyl, wherein said C₁-C₄ hydrocarbyl substituent may optionally contain one double or triple bond;

R₂₂ is independently at each occurrence selected from hydrogen, C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₈ cycloalkyl, (C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), and (C₁-C₄ alkylene)(C₃-C₈ cycloalkyl);

R₂₂ is independently at each occurrence selected from hydrogen, C₁-C₁₄ alkyl, C₁-C₁₄ haloalkyl, C₃-C₆ alkenyl, C₃-C₆ alkynyl, C₃-C₈ cycloalkyl, (C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), and (C₁-C₄ alkylene)(C₃-C₈ cycloalkyl);

R₂₃ is independently at each occurrence selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₂-C₈ alkoxyalkyl, C₃-C₈ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), aryl, -(C₁-C₄ alkylene)aryl, piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, and thiomorpholine;

R₂₄ and R₂₅ are independently at each occurrence selected from hydrogen, -C₁-C₄ alkyl, C₁-C₄ haloalkyl, -(C₁-C₄ alkylene)OH, -(C₁-C₄ alkylene)-O-(C₁-C₄ alkyl), -(C₁-C₄ alkylene)-O-(C₃-C₅ cycloalkyl), C₃-C₈ cycloalkyl, -(C₁-C₄ alkylene)(C₃-C₈ cycloalkyl), -(C₃-C₈ cycloalkylene)(C₃-C₈ cycloalkyl), -C₄-C₈ heterocyclohydrocarbyl, -(C₁-C₄ alkylene)(C₄-C₈ heterocyclohydrocarbyl), -(C₃-C₈ cycloalkylene)(C₄-C₈ heterocyclohydrocarbyl), aryl, and -(C₁-C₄ alkylene)(aryl), wherein the -C₄-C₈ heterocyclohydrocarbyl groups can each independently optionally be substituted with aryl, CH₂-aryl, or C₁-C₄ hydrocarbyl, and can optionally contain one or two double or triple bonds; or, when R₂₄ and R₂₅ are as NR₂₄R₂₅, -C(O)NR₂₄R₂₅, -(C₁-C₄ alkylene)NR₂₄R₂₅, or -NHCONR₂₄R₂₅, then NR₂₄R₂₅ may further optionally form a 4 to 8 membered heterocyclic ring optionally containing one or two further hetero members


independently selected from $S(O)_m$, oxygen, nitrogen, and NR_{12} , and optionally containing from one to three double bonds;

R_{26} is independently at each occurrence selected from C_1 - C_4 alkyl, C_1 - C_4 haloalkyl, C_3 - C_8 cycloalkyl, $-(C_1$ - C_4 alkylene)(C_3 - C_8 cycloalkyl), $-(C_3$ - C_8 cycloalkylene)(C_3 - C_8 cycloalkyl), aryl, and $-(C_1$ - C_4 alkylene)(aryl); and

wherein each m is independently zero, one, or two,

with the proviso that heterocyclohydrocarbylene groups of the compound of formula II, do not comprise any $-S-S-$, $-S-O-$, $-N-S-$, or $-O-O-$ bonds, and do not comprise more than two oxygen or $S(O)_m$ heterologous members.

Claim 2. (previously presented) A compound according to claim 1 of the formula



or a pharmaceutically acceptable salt thereof, wherein

A is $-CR_7$ or N;

B is $-NR_1R_2$, $-CR_1R_2R_{11}$, $-C(=CR_2R_{12})R_1$, $-NHCHR_1R_2$, $-OCHR_1R_2$, $-SCHR_1R_2$, $-CHR_2OR_{12}$, $-CHR_2SR_{12}$, $-C(S)R_2$ or $-C(O)R_2$;

Y is $-CH$ or N;

R_1 is C_1 - C_6 hydrocarbonyl which may optionally be substituted with one or two substituents R_8 independently selected from the group consisting of hydroxy, fluoro, chloro, bromo, iodo, CF_3 , C_1 - C_4 alkoxy, $-O-CO-(C_1$ - C_4 hydrocarbonyl), $-O-CO-NH(C_1$ - C_4 hydrocarbonyl), $-O-CO-N(C_1$ - C_4 hydrocarbonyl)(C_1 - C_2 hydrocarbonyl), $-NH(C_1$ - C_4

hydrocarbyl), -N(C₁-C₂ alkyl)(C₁-C₄ hydrocarbyl), -S(C₁-C₄ alkyl), -N(C₁-C₄)CO(C₁-C₄ hydrocarbyl), -NHCO(C₁-C₄ hydrocarbyl), -COO(C₁-C₄ hydrocarbyl)hydrocarbyl, -CONH(C₁-C₄ hydrocarbyl), -CON(C₁-C₄ hydrocarbyl)(C₁-C₂ alkyl), CN, NO₂, -SO(C₁-C₄ hydrocarbyl) and -SO₂(C₁-C₄ hydrocarbyl), and wherein said C₁-C₆ hydrocarbyl and the (C₁-C₄)hydrocarbyl moieties in the foregoing R₁ groups may optionally contain one carbon-carbon double or triple bond;

R₂ is C₁-C₁₂ hydrocarbyl, aryl or -(C₁-C₄ hydrocarbylene)aryl wherein said aryl is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, or benzoxazolyl; 3- to 8-membered cycloalkyl or -(C₁-C₆ alkylene)cycloalkyl, wherein one or two of the ring carbons of said cycloalkyl having at least 4 ring members and the cycloalkyl moiety of said -(C₁-C₆ alkylene)cycloalkyl having at least 4 ring members may optionally be replaced by an oxygen or sulfur atom or by N-R₉ wherein R₉ is hydrogen or C₁-C₄ alkyl; and wherein each of the foregoing R₂ groups may optionally be substituted with from one to three substituents independently selected from chloro, fluoro and C₁-C₄ alkyl, or with one substituent selected from bromo, iodo, C₁-C₆ alkoxy, -O-CO-(C₁-C₆ alkyl), -O-CO-N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -S(C₁-C₆ alkyl), CN, NO₂, -SO(C₁-C₄ alkyl), and -SO₂(C₁-C₄ alkyl), and wherein said C₁-C₁₂ hydrocarbyl and the C₁-C₄ hydrocarbylene moiety of said -(C₁-C₄ hydrocarbylene)aryl may optionally contain one carbon-carbon double or triple bond;

or -NR₁R₂ or -CR₁R₂R₁₁ may form a saturated 5- to 8-membered carbocyclic ring which may optionally contain one or two carbon-carbon double bonds and in which one or two of the ring carbons may optionally be replaced by an oxygen or sulfur atom;

R₃ is methyl, ethyl, fluoro, chloro, bromo, iodo, cyano, methoxy, OCF₃, methylthio, methylsulfonyl, CH₂OH, or CH₂OCH₃;

R₄ is hydrogen, C₁-C₄ hydrocarbyl, fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, trifluoromethoxy, -CH₂OCH₃, -CH₂OCH₂CH₃, -CH₂CH₂OCH₃, -CH₂OF₃, CF₃, amino, nitro, -NH(C₁-C₄ alkyl), -N(CH₃)₂, -NHCOCH₃, -NHCONHCH₃, -SO_n(C₁-C₄ hydrocarbyl) wherein n is 0, 1 or 2, cyano, hydroxy, -CO(C₁-C₄ hydrocarbyl), -CHO, cyano or -COO(C₁-C₄ alkyl) wherein said C₁-C₄ hydrocarbyl may optionally contain one double or triple bond and may optionally be substituted with one substituent selected from hydroxy, amino, -NHCOCH₃, -NH(C₁-C₂ alkyl), -N(C₁-C₂ alkyl)₂, -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), C₁-C₃ alkoxy, C₁-C₃ thioalkyl, fluoro, chloro, cyano and nitro;

R₅ is phenyl, naphthyl, thienyl, benzothienyl, pyridyl, quinolyl, pyrazinyl, pyrimidyl, furanyl, benzofuranyl, benzothiazolyl, or indolyl, wherein each of the above groups R₅ is substituted with from one to three substituents independently selected from fluoro, chloro, C₁-C₆ alkyl, and C₁-C₆ alkoxy, or with one substituent selected from hydroxy, iodo, bromo, formyl, cyano, nitro, trifluoromethyl, amino, -(C₁-C₆ alkyl)O(C₁-C₆)alkyl, -NHCH₃, -N(CH₃)₂, -COOH, -COO(C₁-C₄ alkyl), -CO(C₁-C₄ alkyl), -SO₂NH(C₁-C₄ alkyl), -SO₂N(C₁-C₄ alkyl)(C₁-C₂ alkyl), -SO₂NH₂, -NHSO₂(C₁-C₄ alkyl), -S(C₁-C₆ alkyl) and -SO₂(C₁-C₆ alkyl), and wherein the C₁-C₄ alkyl and C₁-C₆ alkyl moieties of the foregoing R₅ groups may optionally be substituted with one or two fluoro groups or with one substituent selected from hydroxy, amino, methylamino, dimethylamino and acetyl;

R₆ is hydrogen or C₁-C₆ alkyl, wherein C₁-C₆ alkyl may optionally be substituted with one hydroxy, methoxy, ethoxy or fluoro group;

R₇ is hydrogen, methyl, fluoro, chloro, bromo, iodo, cyano, hydroxy, -O(C₁-C₄ alkyl), -C(O)(C₁-C₄ alkyl), -C(O)O(C₁-C₄ alkyl), -OCF₃, CF₃, -CH₂OH, -CH₂OCH₃ or -CH₂OCH₂CH₃;

R₁₁ is hydrogen, hydroxy, fluoro, or methoxy;

R₁₂ is hydrogen or C₁-C₄ alkyl; and

R₁₆ and R₁₇ are each independently, hydrogen, hydroxy, ethyl, ethyl, methoxy, or ethoxy, except that R₁₆ and R₁₇ are not both methoxy or ethoxy;

or R₁₆ and R₁₇ together form an oxo (=O) group;

or a pharmaceutically acceptable salt of such compound.

Claim 3. (previously presented) A compound according to claim 2 wherein B is -NR₁R₂, -NHCHR₁R₂, -SCHR₁R₂ or -OCHR₁R₂; R₁ is C₁-C₆ hydrocarbyl, which may optionally be substituted with one hydroxy, fluoro, CF₃, or C₁-C₂ alkoxy group and may optionally contain one double or triple bond; and R₂ is benzyl or C₁-C₆ hydrocarbyl which may optionally contain one carbon-carbon double or triple bond, wherein said C₁-C₆ alkyl or the phenyl moiety of said benzyl may optionally be substituted with fluoro, CF₃, C₁-C₂ alkyl, or C₁-C₂ alkoxy.

Claim 4. (previously presented) A compound according to claim 2 wherein R₁ is C₁-C₆ hydrocarbyl which may be substituted by fluoro, CF₃, hydroxy, C₁-C₂ alkyl or C₁-C₂ alkoxy and which may optionally contain one carbon-carbon double or triple bond.

Claim 5. (original) A compound according to claim 2 wherein R₂ is C₁-C₄ alkyl which may optionally be substituted by fluoro, chloro, CF₃, C₁-C₄ alkyl or C₁-C₄ alkoxy.

Claim 6. (original) A compound according to claim 2 wherein R₃ is methyl, chloro, or methoxy.

Claim 7. (previously presented) A compound according to claim 2 wherein R₄ is methyl, -CH₂OH, cyano, trifluoromethoxy, methoxy, chloro, trifluoromethyl, -COOCH₃, CH₂Cl, -CH₂F, ethyl, amino or nitro.

Claim 8. (original) A compound according to claim 2 wherein R₅ is phenyl substituted with two or three substituents.

Claim 9. (original) A compound according to claim 2 wherein R₆ is hydrogen, methyl or ethyl.

Claim 10. (original) A compound according to claim 2 wherein R₅ is pyridyl substituted with two or three substituents.

Claim 11. (previously presented) A compound according to claim 8 wherein said substituents are selected, independently, from fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, trifluoromethyl, C₁-C₆ hydrocarbyl which may optionally be substituted with one hydroxy, C₁-C₄ alkoxy or fluoro group and which may optionally contain one carbon-carbon double or triple bond, - (C₁-C₄ alkylene)O(C₁-C₂ alkyl), C₁-C₃ hydroxyalkyl, hydroxy, formyl, COO(C₁-C₂ alkyl), - (C₁-C₂ alkylene)amino, and -(C(O))(C₁-C₄ alkyl).

Claim 12. (previously presented) A compound according to claim 10 wherein said substituents are selected, independently, from fluoro, chloro, bromo, iodo, C₁-C₄ alkoxy, trifluoromethyl, C₁-C₆ hydrocarbyl which may optionally be substituted with one hydroxy, C₁-C₄ alkoxy or fluoro group and which may optionally contain one carbon-carbon double or triple bond, -(C₁-C₄ alkylene)O(C₁-C₂alkyl), C₁-C₃ hydroxyalkyl, hydroxy, formyl, - COO(C₁-C₂ alkyl), -(C₁-C₂ alkylene)amino, and -(C(O))(C₁-C₄ alkyl).

Claim 13. (original) A compound according to claim 1, wherein said compound is

N-butyl-[2,5-dimethyl-7-(2,4,6-trimethylphenyl)-6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl]-ethyl-amino; or

4-(butyl-ethylamin)-2,5-dimethyl-7-(2,4,6-trimethylphenyl)5,7-dihydro-pyrrolo[2,3-d]pyrimidin-6-one;

or a pharmaceutically acceptable salt of one of the above compounds.

Claim 14. (previously presented) A pharmaceutical composition comprising an amount of a compound according to claim 1 that is effective in providing the composition with CRF antagonist activity in a mammal to be treated, and a pharmaceutically acceptable carrier.

Claim 15. (previously presented) A pharmaceutical composition according to claim 14, wherein the compound according to claim 1 is present in an amount of between about 0.1 to about 50mg/kg body weight of the mammal.

Claims 16-44 (canceled).

Claim 45 (previously presented). The pharmaceutical composition according to claim 15 wherein the mammal is a human.

Claim 46 (previously presented). A method for binding corticotropin releasing factor in a patient to be treated comprising (a) providing the compound of claim 1; and (b) administering the compound to the patient in an amount effective to bind the corticotropin releasing factor in the patient.

Claim 47 (previously presented). In a method for treating a sleep disorder in a patient wherein a compound useful for treating the sleep disorder is administered to the patient, the improvement comprising also administering to the patient the compound of claim 1 with the compound useful for treating the sleep disorder.

Claim 48 (previously presented). The method according to claim 47, wherein said compound for treating the sleep disorder is selected from the group consisting of tachykinin antagonists, agonists for GABA brain receptors, metanergic compounds, GABA brain receptor agonists, 5HT₂ receptor antagonists, and D4 receptor binding.

Claims 49-50 (cancelled).

Claim 51 (previously presented). In a method for treating emesis in a patient wherein a compound for treating the emesis is administered to the patient, the improvement wherein wherein the compound of claim 1 is also administered to the patient with the compound for treating emesis.

Claim 52 (previously presented). The method according to claim 51, wherein the compound is selected from the group consisting of tachykinin antagonists, 5HT₃ antagonists, GABA agonist and substance P inhibitors.